M&A deals

CP Reports
CP Insight
Current Agreements
CP Knowledge Centre
CP Consulting

Derived from Current Agreements, our editors have selected notable M&A deals from the life sciences in recent weeks – our Featured deals. Subscribe to our weekly newsletter to be updated on new featured deals and much more.

For comprehensive access to all life science deals as they are announced:

Deal Monitor - part of Current Partnering Insight, Deal Monitor allows you to track recent deals by industry sector, therapy area, technology type and stage of development - access now

Current Agreements - search over 40,000 deals to find benchmarks, monitor target company deal structures, identify companies active in your area(s) of interest, and much more - access now

Featured M&A deals

All M&A deals: Deal Monitor | Current Agreements

Merck to buy Schering-Plough for $41.1 billion

March 9, 2009 : big pharma, Merck

Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. more »

Roche expected to seal Genentech deal after upping bid

March 9, 2009 : big pharma, Roche

Roche expected to seal a deal to buy out Genentech after the Swiss drugmaker upped its offer to $45.7 billion.

Shire acquires UCB’s Equasym

February 20, 2009 : big pharma, shire, UCB

Shire will make a cash payment to UCB of EUR55 million for the acquisition of global rights (ex-USA, Canada and Barbados) on completion of the transaction. more »

Lundbeck to buy OVATION Pharmaceuticals for up to $900 million

February 9, 2009 : big pharma, Lundbeck

Lundbeck will make an upfront payment of $600 million upon closing. Additional payments of up to $300 million within one year of closing are contingent upon the achievement of certain product regulatory milestones relating to FDA approval of Ovation’s Sabril treatment for adults with refractory complex partial seizures and children with infantile spasms.

Roche posts hostile bid for Genentech at $42 billion

January 30, 2009 : big pharma, Roche

The offer replaces the public proposal made by Roche on July 21, 2008 to acquire all of the publicly-held shares of Genentech at a price of US$ 89 per share in cash by means of a negotiated merger.

Astellas proposes to acquire CV Therapeutics

January 27, 2009 : Astellas, big pharma

Acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash. more »

Pfizer to buy Wyeth for $68 billion

January 26, 2009 : big pharma, Pfizer

Definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. more »

GlaxoSmithKline buys UCB Group emerging market activities for $667.2 million

January 26, 2009 : big pharma, GlaxoSmithKline, UCB

UCB has agreed with GlaxoSmithKline (GSK), to sell current UCB business and UCB affiliates in selected emerging markets for a cash compensation of EUR 515 million upon closing of the transaction expected in late March 2009. more »

Daiichi to bid for up to 20 percent of Ranbaxy’s Zenotech

January 20, 2009 : big pharma, Daiichi Sankyo

Daiichi Sankyo acquired a 63.9 percent stake in Ranbaxy Laboratories last year. more »

Endo to buy Indevus in $637 million deal

January 7, 2009 :

Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, more »

« Page 1 ... 63, 64, 65, »

Derived from Current Agreements, more featured partnering deals by category:

Big pharma

GSK inks pharma licensing deals with Renaissance Acquisition Holdings

June 4, 2013

GSK seals global pharma licensing development agreement with MorphoSys

June 4, 2013

Pfizer announces pricing of $4 billion debt financing

June 3, 2013

View more featured deals | all deals at Deal Monitor

Big biotech

Blog in Blog: There are no posts that match the selection criteria.View more featured deals | all deals at Deal Monitor

Pharma

M&A news: Stada acquires Thorton & Ross

August 19, 2013

Ophthotech in $85 million IPO financing

August 19, 2013

Abbott Laboratories in joint venture for blood donations

August 19, 2013

View more featured deals | all deals at Deal Monitor

Biotech

Blog in Blog: There are no posts that match the selection criteria.View more featured deals | all deals at Deal Monitor

Diagnostics

Blog in Blog: There are no posts that match the selection criteria.View more featured deals | all deals at Deal Monitor

Medical device

Blog in Blog: There are no posts that match the selection criteria.View more featured deals | all deals at Deal Monitor

Drug delivery

Blog in Blog: There are no posts that match the selection criteria.View more featured deals | all deals at Deal Monitor

Print Friendly, PDF & Email
cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif